Erratum: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263

Oliver A. Cornely; Michael N. Robertson; Shariq Haider; Andrew Grigg; Michelle Geddes; Mickael Aoun; Werner J. Heinz; Issam Raad; Urs Schanz; Ralf G. Meyer; Sarah P. Hammond; Kathleen M. Mullane; Helmut Ostermann; Andrew J. Ullmann; Stefan Zimmerli; M. L.P.S.Van Iersel; Deborah A. Hepler; Hetty Waskin; Nicholas A. Kartsonis; Johan Maertens

doi:10.1093/jac/dkx382

Erratum: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263

Oliver A. Cornely, Michael N. Robertson, Shariq Haider, Andrew Grigg, Michelle Geddes, Mickael Aoun, Werner J. Heinz, Issam Raad, Urs Schanz, Ralf G. Meyer, Sarah P. Hammond, Kathleen M. Mullane, Helmut Ostermann, Andrew J. Ullmann, Stefan Zimmerli, M. L.P.S.Van Iersel, Deborah A. Hepler, Hetty Waskin, Nicholas A. Kartsonis, Johan Maertens

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	3501
Number of pages	1
Journal	Journal of Antimicrobial Chemotherapy
Volume	72
Issue number	12
DOIs	https://doi.org/10.1093/jac/dkx382
State	Published - Dec 1 2017

ASJC Scopus subject areas

Pharmacology
Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1093/jac/dkx382

Cite this

Cornely, O. A., Robertson, M. N., Haider, S., Grigg, A., Geddes, M., Aoun, M., Heinz, W. J., Raad, I., Schanz, U., Meyer, R. G., Hammond, S. P., Mullane, K. M., Ostermann, H., Ullmann, A. J., Zimmerli, S., Iersel, M. L. P. S. V., Hepler, D. A., Waskin, H., Kartsonis, N. A., & Maertens, J. (2017). Erratum: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263. Journal of Antimicrobial Chemotherapy, 72(12), 3501. https://doi.org/10.1093/jac/dkx382

Erratum: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263. / Cornely, Oliver A.; Robertson, Michael N.; Haider, Shariq et al.
In: Journal of Antimicrobial Chemotherapy, Vol. 72, No. 12, 01.12.2017, p. 3501.

Research output: Contribution to journal › Comment/debate › peer-review

Cornely, OA, Robertson, MN, Haider, S, Grigg, A, Geddes, M, Aoun, M, Heinz, WJ, Raad, I, Schanz, U, Meyer, RG, Hammond, SP, Mullane, KM, Ostermann, H, Ullmann, AJ, Zimmerli, S, Iersel, MLPSV, Hepler, DA, Waskin, H, Kartsonis, NA & Maertens, J 2017, 'Erratum: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263', Journal of Antimicrobial Chemotherapy, vol. 72, no. 12, pp. 3501. https://doi.org/10.1093/jac/dkx382

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M et al. Erratum: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263. Journal of Antimicrobial Chemotherapy. 2017 Dec 1;72(12):3501. doi: 10.1093/jac/dkx382

Cornely, Oliver A. ; Robertson, Michael N. ; Haider, Shariq et al. / Erratum : Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263. In: Journal of Antimicrobial Chemotherapy. 2017 ; Vol. 72, No. 12. pp. 3501.

@article{b62097418c6a4a54ba3648570120b385,

title = "Erratum: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263",

author = "Cornely, {Oliver A.} and Robertson, {Michael N.} and Shariq Haider and Andrew Grigg and Michelle Geddes and Mickael Aoun and Heinz, {Werner J.} and Issam Raad and Urs Schanz and Meyer, {Ralf G.} and Hammond, {Sarah P.} and Mullane, {Kathleen M.} and Helmut Ostermann and Ullmann, {Andrew J.} and Stefan Zimmerli and Iersel, {M. L.P.S.Van} and Hepler, {Deborah A.} and Hetty Waskin and Kartsonis, {Nicholas A.} and Johan Maertens",

year = "2017",

month = dec,

day = "1",

doi = "10.1093/jac/dkx382",

language = "English (US)",

volume = "72",

pages = "3501",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Erratum

T2 - Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263

AU - Cornely, Oliver A.

AU - Robertson, Michael N.

AU - Haider, Shariq

AU - Grigg, Andrew

AU - Geddes, Michelle

AU - Aoun, Mickael

AU - Heinz, Werner J.

AU - Raad, Issam

AU - Schanz, Urs

AU - Meyer, Ralf G.

AU - Hammond, Sarah P.

AU - Mullane, Kathleen M.

AU - Ostermann, Helmut

AU - Ullmann, Andrew J.

AU - Zimmerli, Stefan

AU - Iersel, M. L.P.S.Van

AU - Hepler, Deborah A.

AU - Waskin, Hetty

AU - Kartsonis, Nicholas A.

AU - Maertens, Johan

PY - 2017/12/1

Y1 - 2017/12/1

UR - http://www.scopus.com/inward/record.url?scp=85042191580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042191580&partnerID=8YFLogxK

U2 - 10.1093/jac/dkx382

DO - 10.1093/jac/dkx382

M3 - Comment/debate

C2 - 29029280

AN - SCOPUS:85042191580

SN - 0305-7453

VL - 72

SP - 3501

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 12

ER -

Erratum: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this